| Nov 22 |
S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results
|
| Nov 22 |
Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug
|
| Nov 22 |
Replimune climbs after updates on lead drug
|
| Nov 22 |
Replimune's stock surges 19% after-hours on FDA BLA submission
|
| Nov 21 |
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
|
| Nov 12 |
Replimune Group GAAP EPS of -$0.68 beats by $0.09
|
| Nov 12 |
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
|
| Nov 9 |
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
|
| Nov 8 |
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Oct 30 |
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
|
